BACKGROUND: Subhypnotic doses of @entity1875 possess direct antiemetic properties. The authors sought to determine the plasma concentration of @entity1875 needed to effectively manage @entity1209 . METHODS: @entity1 aged 18-70 yr who were classified as American Society of Anesthesiologists physical status 1 or 2 and had surgery during general anesthesia were approached for the study. Only @entity1 who had @entity390 (verbal rating score > 5 on a 0- to 10-point scale), @entity391 in the postanesthetic care unit participated. @entity1875 was administered to these @entity1 to achieve target plasma concentrations of 100, 200, 400, and 800 ng/ml using a computer-assisted continuous infusion device. Target concentrations were increased every 15 min until @entity1 described at least a 50% reduction in symptoms on the verbal rating score. An arterial blood sample was obtained at each step. The measured plasma @entity1875 concentrations were used to analyze data. Blood pressure, heart and respiratory rates, arterial blood saturation, sedation score, and overall satisfaction with treatment were recorded. RESULTS: Of the 89 @entity1 who consented to the study, 15 @entity1 met entry criteria and were enrolled. Five of these @entity1 also had @entity391 when they entered the study. Fourteen @entity1 responded successfully to treatment. One @entity1 did not achieve the required response at plasma concentrations of 830 ng/ml. Hence the success rate for the treatment of @entity1209 was 93%. Among @entity1 who responded, the median plasma concentration associated with an antiemetic response was 343 ng/ml. There was no difference in sedation scores from baseline and no episodes of desaturation. Hemodynamic parameters were stable during the study. CONCLUSIONS: @entity1875 is generally efficacious in treating @entity1209 at plasma concentrations that do not produce increased sedation. Simulations indicate that to achieve antiemetic plasma @entity1875 concentrations of 343 ng/ml, a bolus dose of 10 mg followed by an infusion of approximately 10 microg x kg(-1) x @entity1009 ) are necessary.

Determination of plasma concentrations of XXXX associated with 50% reduction in postoperative @entity390 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity1009 :: ('966', 'Gene') :: ['min(-1'] @entity391 :: ('MESH:D014839', 'Disease') :: ['retching, or vomiting', 'retching or vomiting'] @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol', 'Propofol'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['postoperative nausea and vomiting']
@entity1875 :: (MESH:D015742,Chemical) :: ['propofol']
